EICHORCondition: Diffuse Glioma · Radionecrosis of Brain · High Grade Glioma · Sponsor: Tata Memorial Centre
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Diffuse gliomas are common tumors involving the brain. They are usually treated by surgery followed by radiation and chemotherapy. Radiotherapy is used for the treatment of brain tumors which causes damage to the tumor cells. However, radiotherapy can also affect the surrounding healthy cells in the brain, causing inflammation and swelling in the region, which is known as radio necrosis (RN). This is considered a late side effect of radiation and is seen in 10-25% of patients treated with radiation for brain tumors. Sometimes, radionecrosis can be detected on routine imaging during follow-up without new symptoms (asymptomaticRN). At the same time, in some patients, it can give rise to new symptoms like headaches, weakness, seizures,etc (symptomatic RN). The standard treatment of RN includes steroid medicines called dexamethasone, which is helpful in a proportion of patients. This is a prospective phase 2 study. This study is being conducted to investigate the ability of the drug Chlorophyllin in the treatment of radionecrosis. Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food colouring agent. This is the first time chlorophyllin will be used in the setting of brain radionecrosis. Our primary aim of th…
This description comes directly from the study's public registry record.
Archya Dasgupta, MD, DNB · 02224177000 · archya1010@gmail.com
Tejpal Gupta, MD, DNB · drtejpalgupta@gmail.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Histological diagnosis of diffuse glioma. * Radionecrosis on imaging with new neurological symptoms/ worsening of prior deficits (Stratum A) or * without new symptoms (Stratum B). * Karnofsky Performance Scale (KPS) ≥ 50. Exclusion Criteria: * No tissue diagnosis. * KPS\< 50. * Disease progression * Contraindications to corticosteroids. * Altered mental status with deficits in understanding or inability to consent to the study. * Brainstem glioma * Indeterminate for radionecrosis vs disease progression * Prior treatment with bevacizumab (either for disease progression or radionecrosis)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Tata Memorial Hospital | Mumbai, Maharashtra, India | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016452